Camurus falls after Q3 revenues miss, Kempen still sees "attractive" valuation

Camurus AB

06/11/2025 09:04

** Shares in Camurus CAMX.ST fall 5.4% after the Swedish biotech company posted Q3 revenues below estimates

** Jefferies and Van Lanschot Kempen point out Camurus' revenues of 567 million Swedish crowns ($60.22 million) were below consensus

** This was largely driven by a miss on sales of opioid injection medicine Buvidal, the brokers note

** Camurus also cut its 2025 revenues outlook to 2.3-2.6 billion crowns, down from 2.7-3.0 billion crowns range, which is more than expected, adds Jefferies

** But Kempen still sees current valuation as "extremely attractive" with upcoming pipeline releases which could drive it higher, such as phase 1 data for CAM2056 in obesity in November

** The share was down 5.4% at 08:58 GMT, on track for worst day in two months, if losses hold

($1 = 9.4155 Swedish crowns)

 (Reporting by Vera Dvorakova)

 ((vera.dvorakova@thomsonreuters.com))